Serum level of interleukin‐35 as a potential prognostic factor for gastric cancer

Aims Interleukin‐35 (IL‐35), a novel anti‐inflammatory cytokine, has recently been implicated in tumor development, progression, and survival. However, the relationship between serum IL‐35 levels and gastric cancer (GC) is inconclusive. Here, we performed this study to clarify the role of serum level of IL‐35 in GC patients. Methods We enrolled 180 GC patients and 170 healthy controls and used enzyme‐linked immunosorbent assay to detect serum IL‐35 levels. The clinical relevance between IL‐35 and clinical pathology parameters was assessed. Univariate and multivariate logistic regressions were used to determine the feasibility of IL‐35 as a clinical biomarker. Results We observed that serum IL‐35 levels were significantly higher in GC patients (17.559 ± 13.266 pg/mL) than in healthy controls (8.077 ± 3.801 pg/mL, P